Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

Core Insights - Zymeworks Inc. announced the acceptance of a poster presentation for preliminary results from a Phase 1 study of ZW191, an antibody-drug conjugate targeting folate receptor-α, at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics [1][2] Company Overview - Zymeworks is a clinical-stage biotechnology company focused on developing novel biotherapeutics for difficult-to-treat diseases, including cancer, inflammation, and autoimmune diseases [5] - The company has a diverse pipeline, including the lead product candidate ZW191, which utilizes a proprietary payload, ZD06519, designed to target FRα, a protein found in various challenging cancers [2][4] Product Details - ZW191 targets folate receptor-α, which is expressed in approximately 75% of high-grade serous ovarian carcinomas and about 70% of lung adenocarcinomas [4] - The design of ZW191 supports its ability to internalize into FRα-expressing cells, potentially releasing the active topoisomerase-1 inhibitor to kill tumor cells [4][6] Clinical Development - The Phase 1 study of ZW191 is actively recruiting participants, with preliminary data expected to provide insights into its efficacy in treating advanced solid tumors, including ovarian cancer, endometrial cancer, and non-small cell lung cancer [6][7] - A live webcast will be held on October 23, 2025, to discuss the data presented, featuring the lead author and Zymeworks senior management [3]